BridgeBio Pharma

Yahoo Finance • 4 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma, Inc. PALO ALTO, Calif., July 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced th... Full story

Yahoo Finance • 5 months ago

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. - Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and c... Full story

Yahoo Finance • 7 months ago

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BridgeBio Pharma, Inc. - In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data demon... Full story

Yahoo Finance • 8 months ago

BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

March 4 (Reuters) - BridgeBio Pharma has granted German drugmaker Bayer an exclusive license to commercialize its heart disease drug in Europe, the companies said on Monday. The experimental drug, acoramidis, is being developed as an oral... Full story

Yahoo Finance • 8 months ago

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

BridgeBio Pharma, Inc. - BridgeBio grants Bayer exclusive license to commercialize acoramidis as a treatment for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe - BridgeBio to receive royalties according to a tiere... Full story

Yahoo Finance • 9 months ago

14 Best Medical Stocks To Invest In According to Hedge Funds

In this piece, we will take a look at the 14 best medical stocks to invest in according to hedge funds. If you want to skip our overview of the medical and healthcare industry, then you can take a look at the 5 Best Medical Stocks To Inves... Full story

Yahoo Finance • 10 months ago

BridgeBio Pharma Secures up to $1.25 Billion of Capital from Blue Owl and CPP Investments to Accelerate the Development and Launch of Genetic Medicines

BridgeBio Pharma, Inc. - The raise includes $500 million in cash from Blue Owl and CPP Investments in exchange for a 5% royalty on future global net sales of acoramidis - The raise also includes a $450 million credit facility from Blue O... Full story

Yahoo Finance • 10 months ago

16 Best Mid Cap Growth Stocks To Buy Now

In this article, we will take a detailed look at the16Best Mid-Cap Growth Stocks To Buy Now. For a quick overview of such stocks, read our article 5Best Mid-Cap Growth Stocks To Buy Now. Investors are hopeful that small- and mid-cap stock... Full story

Yahoo Finance • 10 months ago

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

BridgeBio Pharma, Inc. The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class orally bioavailable and potentially highly potent small molecule direct... Full story

Yahoo Finance • 10 months ago

13 High Growth Healthcare Stocks to Buy

In this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this artic... Full story

Yahoo Finance • 12 months ago

BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related hospitalization) was met (Win Ratio of 1.8) with a highly statistically significant p-value (... Full story

Yahoo Finance • 12 months ago

BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023

PALO ALTO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that additio... Full story

Yahoo Finance • last year

BridgeBio Pharma Inc (BBIO) Reports Q3 2023 Financial Results

BridgeBio Pharma Inc (NASDAQ:BBIO) reported Q3 2023 revenue of $4.1 million, compared to $0.3 million in Q3 2022. The company ended Q3 2023 with $522 million in cash, cash equivalents, and short-term restricted cash. BBIO raised approximat... Full story

Yahoo Finance • last year

BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update

- Presented detailed positive results from the ATTRibute-CM Phase 3 study of acoramidis at the European Society of Cardiology (ESC) Congress, demonstrating that patients survived more and were hospitalized less than has been seen in other... Full story

Yahoo Finance • last year

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on Octo... Full story

Yahoo Finance • last year

BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria - Rapid and sustained impact of encaleret on mineral homeostasis was observe... Full story

Yahoo Finance • last year

BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate endpoint in LGDM2I/R9 - Long-term data fr... Full story

Yahoo Finance • last year

BridgeBio Pharma Announces $250 Million Private Placement Equity Financing

- $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US - BridgeBio anticipates this raise, coupled with several less dilutive financin... Full story

Yahoo Finance • last year

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA and EMA alignment was reached on the a... Full story

Yahoo Finance • last year

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both variant and wi... Full story